• △◠○◡◇ Fabulations
  • ▩ Approaches
  • <<<<    about::  >>>>
  • ʬʭ Multi Filter
      • Materials
      • Approaches
      • Fabulations
      • People/Orgs
      • Bits of Narration
  • ⌕⌕ Search Materials

84 object Results
  • Sort by:
  • Identifier
  • Title
  • Sort order:
  • Ascending
  • Descending
  • Download results as:
  • Checklist
  • PDF (thumbnails)
  • Excel (basic information)
  • PowerPoint (basic information)

approach:
ZQQW4XX2
Positivrat Schweiz - Misère rund um die Hepatitis-C-Therapien: Atupri bezahlt à tout prix nicht!
ZF5HP5PV
The latest patent application of Hepatitis C drug Sovaldi of Gilead is rejected in China | Lexology
Z5AGNYET
Interferon production by genetic engineering.
YURQAGXI
Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy
YFLSD3I9
Genetic organization and diversity of the hepatitis C virus.
YECHCX4Q
Biological Medicine and the Survival of the Person
XMKJQXUP
GenBank. Nucleic Acids Res. 45(D1):D37-D42 (2017)
XJV92XD9
The Origin of Hepatitis C Virus
W4E3GJKM
Depression, fatigue and neurocognitive deficits in chronic hepatitis C
VWAJD4BG
Handbook of Hepatitis C
VSHTX9XY
Modest_Witness@Second_Millennium. FemaleMan_Meets_OncoMouse: Amazon.de: Donna J. Haraway, Thyrza Goodeve: Amazon.de
VRFDF6GQ
Corporate Overview - Pharmasset, Inc.
T2JGMH7T
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin
SVVXKA89
Hepatitis C: Epidemiologie, natürlicher Verlauf und Diagnostik
STZDLGLN
Interferon Set to Treat Hepatitis
SNDKI86X
Natco tries to block hepatitis C patent in India / General / Generics / Home - GaBI Online - Generics and Biosimilars Initiative
RXEDQ5AD
Die Problematik der Nutzung von Zwangslizenzen durch Staaten ohne eigene Pharmaindustrie: Zur instrumentellen Umsetzung von Art. 6 der Erklärung zum TRIPs und zum öffentlichen Gesundheitswesen#
RGJIV865
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
R7WUJHP6
Hepatitis C die stille Epidemie: Eine Informationsbroschüre der forschenden pharmazeutischen Firmen der Schweiz
QTTH8PSL
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
QS3KDFMI
Chiron challenged on hepatitis-C patent
QPG7B895
Gilead to Buy Pharmasset for $11 Billion to Win in Hepatitis
QM3G8NJF
Molecular Biopolitics, Somatic Ethics and the Spirit of Biocapital
QBEBZJAN
Human tumor-associated viruses and new insights into the molecular mechanisms of cancer
Q9RNVVN9
India announces new trademark, patent policy amid global pressure
Q7V5BLE6
Compulsory Licences Needed For Affordable Hepatitis C Innovative Drug Regimens
PNXGJUS2
Heilmittel mit finanziellen Nebenwirkungen
P58K5S32
Gilead bets $11 billion on hepatitis in Pharmasset deal
NN5CZW2U
Hepatitis C
NHDVXHCL
Transformation of Pseudomonas putida and Escherichia coli with plasmid-linked drug-resistance factor DNA.
Nationalrat_17.3027
Nationalrat Interpellation 17.3027 | Ist die Sicherheit der Medikamente auf dem Gesundheitsmarkt Schweiz noch gewährleistet?
N9ACJJMZ
Global Access | Gilead
MQ5C3IXF
Eine Packung Pillen für 19’000 Franken
KNUKHFTN
Hepatitis C
KK9MEU5V
Pharco Pharmaceuticals
K9P8T5XG
Hepatitis C wait is over - Leo Messi vs. Melanie. #StopTheWait
Next 36

Filter by

object type

Blog Posts (3)
Book Sections (4)
Books (8)
Cases (3)
Conference Papers (1)
Documents (3)
Hearings (2)
Journal Articles (26)
Newspaper Articles (8)
Patents (1)
Reports (2)
Statutes (1)
Video Recordings (1)
Webpages (21)
and 7 more

person

United States Securities and Exchange Commission (SEC) (1)
Abaza, Deya (1)
ADIS (1)
HCV Advocate (1)
Aeple, Natalia (1)
Andino, Raul (1)
Atlan, Henri (1)
and 165 more